August 2013
Urology Times;Aug2013, Vol. 41 Issue 9, p11
Statistics are presented on the percentage of mortality risk for prostate cancer every six months of use of metformin.


Related Articles

  • Diabetes drug lowers PCa-specific, all-cause mortality. Krader, Cheryl Guttman // Urology Times;Aug2013, Vol. 41 Issue 9, p11 

    The article focuses on a retrospective study regarding the effectiveness of metformin on diabetic men diagnosed with prostate cancer. It says that the said drug helps in reducing cancer-specific and all-cause mortality, an in exposure to the said drug increases the cumulative duration of...

  • Diabetes drug may delay prostate cancer progression.  // Mayo Clinic Health Letter;Jan2014, Vol. 32 Issue 1, p4 

    The article reports on the results of a study which found that the diabetes drug metformin may delay progression of prostate cancer, published in a 2013 issue of the "Journal of Clinical Oncology."

  • Phase 2 Clinical Trial Demonstrates Benefits Of Metformin In Prostate Cancer. Pryce, A. // Life Extension;Apr2014, p2 

    The article discusses research being done on the treatment of patients with castration-resistant prostate cancer using metformin, published in the January 4, 2014 issue of the journal "European Urology."

  • New listings on Australian PBS.  // PharmacoEconomics & Outcomes News;Jan2014, Issue 694, p9 

    The article reports that patients with diabetes will receive alogliptin/metformin through the Pharmaceutical Benefits Scheme (PBS) of the Australian government starting February 1, 2014.

  • Metformin may protect against intrahepatic cholangiocarcinoma in diabetes.  // Endocrine Today;Jan2013, Vol. 11 Issue 1, p18 

    The article reports on a study which found that patients with diabetes who received metformin were at reduced risk for intrahepatic cholangiocarcinoma, whereas biliary tract disease, cirrhosis, diabetes and smoking increased that risk.

  • Diabetes treatment, prevention research shows promise. Coopman, Robert // Chain Drug Review;11/23/2015, Vol. 37 Issue 19, p26 

    The article reports on the progress of diabetes research as they pertain to the efficacy of metformin for treating cardiovascular disease in patients with or without diabetes and the possibility of islet cell transplantation and regeneration.

  • Metformin Use Correlates with Reduced Risk of Gallstones in Diabetic Patients: A 12-Year Follow-up Study. Kuan-Fu Liao; Hsun-Yang Chuang; Shih-Wei Lai // Frontiers in Pharmacology;10/24/2017, p1 

    Objective: Few studies are available on the association between gallstones and metformin use. The objective of the study was to determine whether metformin use is associated with gallstones. Methods: A population-based retrospective cohort study was conducted using the database of the Taiwan...

  • Metformin Helps Some Cancer Patients.  // Life Extension;Jul2012, Vol. 18 Issue 7, p4 

    The article discusses an article by Christian Nordqvist published in a 2012 issue of "Medical News Today" which reported that the popular diabetes drug metformin may be beneficial to patients with several types of cancer, including prostate cancer, pancreatic cancer and liver cancer.

  • Metformin Shows Promise For Late-Stage Prostate Cancer.  // Life Extension;Jun2015, p21 

    The article discusses research being done on the potential benefit of metformin for patients with late-stage prostate cancer, which references a study by Xiaoqui Liu and colleagues published in the January 23, 2015 issue of the "Journal of Biological Chemistry."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics